February 22, 2024 07:10 AM EST

Researchers detail data from first 15 autoimmune disease patients treated with CAR-T — and outstanding questions

Amber Tong

The team of German researchers who first reported clinical data backing the idea of using CAR-T cell therapies to treat autoimmune disorders has spelled out …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Researchers detail data from first 15 autoimmune disease patients treated with CAR-T — and outstanding questions

Amber Tong

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

CMS explains what went into its first round of drug price negotiations

Re­searchers de­tail da­ta from first 15 au­toim­mune dis­ease pa­tients treat­ed with CAR-T — and out­stand­ing ques­tions

Amber Tong

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Researchers detail data from first 15 autoimmune disease patients treated with CAR-T — and outstanding questions

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

CMS explains what went into its first round of drug price negotiations